Drug Profile
Bevacizumab biosimilar - Bio-Thera Solutions
Alternative Names: Avzivi; BAT 1706; POBEVCYLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Bio-Thera Solutions
- Developer BeiGene; Bio-Thera Solutions
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Colorectal cancer; Non-small cell lung cancer
- Registered Cervical cancer; Glioblastoma; Renal cell carcinoma
- Phase II Liver cancer
- No development reported Cancer
Most Recent Events
- 01 Feb 2024 BeiGene completes a phase II trial in Liver cancer (First-line therapy, Late-stage disease, Combination therapy) in Taiwan and China (IV) (NCT04948697)
- 03 Jan 2024 Bevacizumab biosimilar licensed to Macter International in Pakistan and Afghanistan
- 07 Dec 2023 Registered for Cervical cancer (Metastatic disease, Recurrent) in USA (IV)